CCO Treatment Updates
Focus on the Virus: A New Paradigm for the Management and Treatment of HBV
Understanding HBV: Viral Load and Disease Progression |
Module 1 of 3 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Ching-Lung Lai, MD, discusses data indicating the importance of HBV DNA levels in disease progression, and the potential mechanisms underlying this relationship.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the significance of HBV DNA levels in patients infected with HBV in early childhood
- Recount data regarding the role of viral load on disease progression in patients infected with HBV
- Discuss the role of HBV DNA in choosing when to treat and in evaluating on-treatment outcomes as described in current treatment guidelines
|
New Measures of Treatment Success: Recent Data on Potency and On-Treatment Response |
Module 2 of 3 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Robert G. Gish, MD, discusses the latest clinical evidence regarding the importance of drug potency and long-term therapy in achieving optimal outcomes in the treatment of chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of HBV DNA levels in the management of patients with chronic hepatitis B
- Review the clinical data for approved and investigational agents for the treatment of chronic hepatitis B
- Discuss the relationship between viral suppression and outcomes in the management of patients with chronic hepatitis B
|
Management of Resistance: Implications for Treatment Choice |
Module 3 of 3 |
|
CME Program Director: Emmet B. Keeffe, MD, MACP
- Jean-Michel Pawlotsky, MD, PhD
|
|
|
Jean-Michel Pawlotsky, MD, PhD, reviews clinical strategies for preventing and managing drug resistance in patients with chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review current data regarding causes and rates of HBV resistance
- Describe prevention strategies for reducing the risk of HBV resistance development
- Discuss management strategies for hepatitis B patients with resistance to antivirals
|
Interactive Case Challenges
Management of an HBeAg-Negative Patient With Cirrhosis and Elevated Alanine Aminotransferase
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Robert G. Gish, MD, describes the management of a recently diagnosed HBeAg-negative patient presenting with elevated ALT.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe clinical data on current treatment options for chronic hepatitis B
- Discuss factors in determining candidacy for hepatitis B therapy in HBeAg-negative patients
- Recount data on the optimal management of hepatitis B patients with decompensated disease
|
Management of an HBeAg-Positive Patient With Borderline-Normal ALT and Family History of Liver Cancer
|
CME Program Director: Emmet B. Keeffe, MD, MACP
|
|
Paul Martin, MD, discusses management decisions for a patient with borderline normal ALT, a family history of hepatocellular carcinoma, and HBeAg-positive serostatus.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss patient characteristics and tests involved in deciding when to treat HBeAg-positive patients
- Describe screening procedures for HBV-infected patients with hepatocellular carcinoma
- List goals of therapy for patients with HBeAg-positive chronic hepatitis B
|
CCO Slidesets
Viral Load and Disease Progression
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 814 KB
| Date posted: 10/31/2006
|
New Measures of Treatment Success: Recent Data on Potency and On-Treatment Response
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 632 KB
| Date posted: 10/31/2006
|
Management of Resistance: Implications for Treatment Choices
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 876 KB
| Date posted: 10/31/2006
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|